Vor Biopharma (NASDAQ:VOR) Price Target Raised to $15.00

Vor Biopharma (NASDAQ:VOR) had its target price boosted by Wedbush to $15.00 in a report released on Tuesday morning,Benzinga reports. Wedbush currently has a neutral rating on the stock.

Several other equities research analysts have also issued reports on VOR. Citigroup assumed coverage on Vor Biopharma in a research note on Friday, January 9th. They set a “buy” rating and a $50.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Wells Fargo & Company started coverage on Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective on the stock. Jefferies Financial Group assumed coverage on Vor Biopharma in a research report on Monday. They issued a “buy” rating and a $50.00 target price for the company. Finally, TD Cowen initiated coverage on Vor Biopharma in a research note on Wednesday, December 17th. They issued a “buy” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Vor Biopharma has an average rating of “Moderate Buy” and a consensus price target of $50.67.

Vor Biopharma Stock Performance

NASDAQ VOR opened at $18.05 on Tuesday. Vor Biopharma has a 52-week low of $2.62 and a 52-week high of $65.80. The company has a fifty day moving average of $14.19 and a 200-day moving average of $17.73. The company has a market capitalization of $187.90 million, a P/E ratio of -0.05 and a beta of 1.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Vor Biopharma in the fourth quarter worth about $36,000. Goldman Sachs Group Inc. boosted its holdings in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the period. XTX Topco Ltd purchased a new stake in Vor Biopharma during the 2nd quarter valued at about $66,000. Chung Wu Investment Group LLC bought a new position in Vor Biopharma during the 4th quarter worth approximately $109,000. Finally, Susquehanna Portfolio Strategies LLC bought a new position in Vor Biopharma during the 4th quarter worth approximately $134,000. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).